Drug Channels

MARCH 3, 2023

Jan discusses digital hubs and the benefits they offer both patients on specialty therapies and their health care providers. To learn more, download AssistRx's free 61-page eBook: Specialty Drug Patient Support Programs: 2022 Progress Report. Read on for Jan’s insights. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Therapies 97

Therapies Drugs 97

Drug Channels

SEPTEMBER 8, 2023

Nasir discusses how hubs help patients initiate and adhere to drug therapies. Learn more by downloading CareMetx’s full report: The Evolving Landscape of Digital Healthcare Hubs. Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Read on for Nasir’s insights.

Pharmaceuticals 97

Pharmaceuticals Therapies Production Drugs 97

Drug Channels

MARCH 22, 2024

Adam discusses how patients seeking to access specialty therapies can benefit from a digital intake approach. To learn about AssistRx’s digital intake solutions, download Digital Intake for Specialty Drug Programs: Q1 2024 Progress Report.

Pharmaceutical Companies 98

Pharmaceutical Companies Therapies Pharmaceuticals Drugs 98

Drug Channels

AUGUST 11, 2023

Today’s guest post comes from Rebecca Cotton, Executive Director of Strategy & Product Innovation at Cardinal Health ™ Sonexus ™ Access and Patient Support Rebecca discusses the essential features biopharmaceutical manufacturers should seek in a digital hub that will help patients get their therapies faster.

Therapies 94

Therapies Production Drugs 94

Drug Channels

FEBRUARY 2, 2024

She highlights how GoodRx’s integrated pharma copay cards help to improve medication access, therapy adherence, and overall health outcomes. Click here to download the full report and learn more about partnering with GoodRx to drive patient access for your brand. Read on for Divya’s insights.

Therapies 98

Therapies Marketing Research Drugs 98

Fierce BioTech

NOVEMBER 1, 2023

Plasmid DNA Design Considerations for Cell and Gene Therapy Cell and Gene therapy organizations must balance the need for rapid clinical progression and stringent quality expectations throughout development.

DNA 52

DNA Therapies RNA 52

Drug Channels

MARCH 10, 2023

Stacey discusses digital hubs and the affordability advantages they offer both patients on specialty therapies and their health care providers. Download AssistRx's free 61-page eBook here: Specialty Drug Patient Support Programs: 2022 Progress Report.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Therapies Marketing 98

Drug Channels

AUGUST 18, 2023

Divya discusses the challenges patients face in accessing specialty therapies prescribed by their healthcare providers. Learn more about GoodRx’s insights and solutions for specialty treatments by downloading their free yellow paper: Access and Affordability Insights: Differences Across Specialties.

Treatment 98

Treatment Therapies Drugs 98

Fierce BioTech

OCTOBER 19, 2023

How cell and gene therapies are forcing sponsors to rethink safety and efficacy monitoring In this whitepaper, we look at how the industry is rising to the challenge, focusing on how cell and gene therapies are radically improving health outcomes and the technologies and techniques that are facilitating their development. Download Now.

Therapies 52

Therapies Drug Development Treatment Research 52

Fierce BioTech

JUNE 1, 2023

Download here! DCI cell therapy Puerto Rico cost-effectiveness Advanced Cell Technology Resource Type Whitepaper investpr logo.png Thu, 06/01/2023 - 10:21 Content Channel Diagnostics Devices Clinical Data Biotech Research Landing Page Url More Info Byline Sponsored by: Invest Puerto Rico

Therapies 52

Therapies Research 52

Fierce BioTech

MAY 29, 2024

Top 5 Reasons for Futureproofing Cell Therapy Development Starting with high quality reagents is one good way to futureproof cell therapy programs. Download this whitepaper examine when and how to transition to GMP critical reagents.

Therapies 40

Therapies 40

Fierce BioTech

JUNE 6, 2023

Accelerating the Development of Nucleic Acid Therapies at Harwell Science and Innovation Campus Harwell Campus offers rich opportunities for pioneering NAT technology on all fronts, and the campus is attracting biotechnology companies of all sizes – from Moderna to start-ups to Government research institutes and accelerators. Download here!

Science 52

Science Therapies Molecular Biology Government 52

Fierce BioTech

SEPTEMBER 30, 2024

Gene therapy manufacturing: Custom and GMP-grade reagents to accelerate your scale-up plan Download now to learn how gene therapy manufacturers can overcome the unique challenges of scaling production.

Therapies 40

Therapies Production 40

DrugBank

AUGUST 20, 2024

You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy. We provide insights into how you can improve efficiency, success rates, and ultimately bring more effective therapies to market.

Therapies 98

Therapies Pharmaceuticals Disease Research 98

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. View original content to download multimedia: [link].

Therapies 52

Therapies Clinical Trials Science Laboratories 52

Drug Channels

SEPTEMBER 10, 2021

She argues that such a solution improves the provider experience, enhances the patient experience, and accelerates speed to therapy. To learn about CoverMyMeds’ integrated patient support services solution, download the free Medication Access Report: Healthcare Technology. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc.

Therapies 45

Therapies Production Drugs 45

PPD

DECEMBER 16, 2024

Internal costs: The complexity of protocol designs a necessity for innovative therapies often requires more diverse patient populations, more extensive data collection and sophisticated trial methodologies, all of which demand higher financial outlays. Nearly 39% of sponsors cite these costs as primarily driven by complex protocols.

Drug Development 52

Drug Development Clinical Trials Compliance Trials 52

The Pharma Data

NOVEMBER 1, 2020

Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. Maryland , US), a leading gene therapy company. Maryland , US), a leading gene therapy company. PARIS , Nov.

Therapies 52

Therapies Science Treatment Disease 52

PPD

OCTOBER 31, 2024

These internal issues are compounded by external pressures like inflation, the development of innovative therapies that require complex protocols and the need to comply with shifting regulatory requirements. Download the full report The post Key Trends Drug Developers Need to Know to Succeed appeared first on PPD.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

Fierce BioTech

OCTOBER 22, 2024

Setting the Standard in CGT With unique perspectives from key opinion leaders, this whitepaper examines the challenges associated with process development and manufacturing of cell and gene therapies. Download this free guide to learn how we are setting the standard in cell and gene therapy, together.

Therapies 52

Therapies 52

Fierce BioTech

AUGUST 14, 2024

Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Epilepsy Clinical Trials Finding an effective epilepsy treatment can be arduous.

Clinical Trials 52

Clinical Trials Trials Therapies Treatment 52

Fierce BioTech

NOVEMBER 26, 2024

Download now. Download now. Cell & Gene Therapy Resource Type Whitepaper Avantor-logo 250x190.png png Tue, 11/26/2024 - 19:54 Fierce Biotech Homepage Landing Page Url Download Now Byline Sponsored By: Avantor Cell & Gene Therapy Resource Type Whitepaper Avantor-logo 250x190.png

Therapies 52

Therapies 52

Fierce BioTech

MAY 30, 2024

Quantify Cancer With Methylation-Based ctDNA Detection Download this resource to accelerate your oncology clinical trials, optimize patient enrollment, and monitor minimal residual disease and molecular response effectively.

Clinical Trials 52

Clinical Trials DNA Trials Therapies 52

Drug Channels

APRIL 23, 2021

Erica discusses four technology areas that the healthcare network can embrace to increase speed to therapy, affordability, and adherence. To learn more about CoverMyMeds’ technology solutions, download their new whitepaper: Helping Patients Access Specialty Therapies: Autoimmune Conditions. Free download ).

Therapies 52

Therapies Drugs 52

Fierce BioTech

MARCH 28, 2024

How Medical Affairs is Charting the Course for Pre- and Post-Launch Strategies Early involvement of Medical Affairs in advanced therapies is pivotal. Download to learn how Medical Affairs redefines healthcare and improves patient outcomes. Download to learn how Medical Affairs redefines healthcare and improves patient outcomes.

Biosimilars 52

Biosimilars Therapies Disease Drugs 52

Drug Channels

MAY 22, 2023

WHAT YOU WILL LEARN As expensive specialty therapies come to dominate drug spending, pharmaceutical manufacturers are paying a growing share of patents’ out-of-pocket costs for these prescriptions. Or, download this spreadsheet and email your registrants’ information to Tamra Feldman ( admin@drugchannels.net ).

Pharmacy 97

Pharmacy Drugs Marketing Therapies 97

The Pharma Data

JANUARY 27, 2021

HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG). View original content to download multimedia: [link]. CAMBRIDGE, Mass.

Therapies 40

Therapies Treatment International Licensing 40

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. View original content to download multimedia: [link]. SOURCE Eli Lilly and Company.

Therapies 52

Therapies Production Government Disease 52

PPD

FEBRUARY 10, 2025

By harnessing the full range of innovative technologies and taking advantage of an FSP partners extensive skills and experience, sponsors are able to bring their therapies to market more quickly and within budget even in the face of complicated global regulations and widely fluctuating workloads.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

Fierce BioTech

JULY 25, 2023

How combining datasets from multiple sources can inform and improve commercial strategies Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.

Pharma Companies 52

Pharma Companies Government Therapies Disease 52

The Pharma Data

NOVEMBER 23, 2020

CMTI) has received 60+ red light therapy (RLT) modules for initial photonics testing and product fabrication. View original content to download multimedia: [link]. FRISCO, Texas , Nov. 24, 2020 /PRNewswire/ — Curtis Mathes Corporation (OTC: TLED) subsidiary, Curtis Mathes Therapeutics, Inc.

Therapies 40

Therapies Treatment Production Research 40

The Pharma Data

SEPTEMBER 15, 2020

Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. Balance risk and innovation in regulation using new digital-therapy products.

Regulations 52

Regulations Production Therapies Treatment 52

Fierce BioTech

NOVEMBER 16, 2023

Beyond cfDNA: Harnessing the Power of Exosomes to Improve Sensitivity for Cancer Mutation Detection Liquid biopsy markers are advantageous because they can be used to assess overall prognosis, response to therapy, and likelihood of relapse or progression. Download now.

RNA 52

RNA DNA Therapies Treatment 52

The Pharma Data

SEPTEMBER 1, 2020

Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. Download Your Copy.

Clinical Trials 52

Clinical Trials Trials Regulations Production 52

Fierce BioTech

JULY 28, 2023

Download here! jsabatino Fri, 07/28/2023 - 11:29 In this white paper, we look at the past, present and future of antibodies as therapies, explaining how the modality became a key pillar of the biopharma industry—and looking forward to the methods and technologies that could unleash its full potential in the years to come.

Therapies 52

Therapies Drug Development Research Drugs 52

Fierce BioTech

SEPTEMBER 16, 2024

How next-generation phage display libraries are accelerating antibody developability Download now to learn how a next-generation phage library is overcoming the limitations of traditional antibody discovery platforms, enhancing the discovery of highly specific and effective antibody-based therapies.

Therapies 40

Therapies Drug Development Research Drugs 40

Drug Channels

AUGUST 14, 2020

Julia discusses the challenges of both access to therapy and patient adherence, specifically during the COVID-19 pandemic. To learn more, download the CoverMyMeds case study, Overcoming Medication Access Barriers Caused by Prior Authorization.

Therapies 52

Therapies Drugs 52